How Prostate Cancer Therapies Compare by Cost and Effectiveness

Surgery Ranks as the Most Cost-Effective Type of Treatment, According to UCSF-Led Study

By Jason Bardi    |   UCSF.edu | January 4, 2013

How Prostate Cancer Therapies Compare by Cost and Effectiveness

Surgery Ranks as the Most Cost-Effective Type of Treatment, According to UCSF-Led Study

The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness is reported this week by a team of researchers at UCSF.

Appearing in the British Journal of Urology International, the work analyzed 232 papers published in the last decade that report results from clinical studies following patients with low-, intermediate- and high-risk forms of prostate cancer who were treated with one or more of the standard treatments – radiation therapy, surgery, hormone therapies and brachytherapy.
 
The analysis shows that for people with low-risk prostate cancer, the various forms of treatment vary only slightly in terms of survival – the odds of which are quite good for men with this type of cancer, with a 5-year cancer-specific survival rate of nearly 100 percent. But the cost of radiation therapy is significantly more expensive than surgery for low-risk prostate cancer, they found.
 
For intermediate- and high-risk cancers, both survival and cost generally favored surgery over other forms of treatment – although combination external-beam radiation and brachytherapy together were comparable in terms of quality of life-adjusted survival for high-risk prostate cancer.
 
“Our findings support a greater role for surgery for high-risk disease than we have generally seen it used in most practice settings,” said urologist Matthew Cooperberg, MD, MPH, who led the research. Cooperberg is an assistant professor of urology and epidemiology and biostatistics in the UCSF Helen Diller Family Comprehensive Cancer Center.
 
The UCSF Helen Diller Family Comprehensive Cancer Center is one of the country’s leading research and clinical care centers, and it is the only comprehensive cancer center in the San Francisco Bay Area.
 
Many Treatment Options, but Few Cost Analyses
Localized prostate cancer accounts for about 81 percent of the quarter-million cases of prostate cancers that occur in the United States every year, according to the National Cancer Institute. It is defined by tumors that have not metastasized and spread outside the prostate gland to other parts of the body.
 

Read more at UCSF.edu